Daniel Paul Regan Net Worth

The estimated Net Worth of Daniel Paul Regan is at least 237 千$ dollars as of 30 January 2015. Daniel Regan owns over 9,847 units of Intercept Pharmaceuticals Inc stock worth over 211,109$ and over the last 12 years Daniel sold ICPT stock worth over 25,768$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Daniel Regan ICPT stock SEC Form 4 insiders trading

Daniel has made over 5 trades of the Intercept Pharmaceuticals Inc stock since 2014, according to the Form 4 filled with the SEC. Most recently Daniel exercised 9,847 units of ICPT stock worth 371,133$ on 30 January 2015.

The largest trade Daniel's ever made was exercising 20,000 units of Intercept Pharmaceuticals Inc stock on 5 March 2014 worth over 753,800$. On average, Daniel trades about 3,465 units every 30 days since 2013. As of 30 January 2015 Daniel still owns at least 11,111 units of Intercept Pharmaceuticals Inc stock.

You can see the complete history of Daniel Regan stock trades at the bottom of the page.

What's Daniel Regan's mailing address?

Daniel's mailing address filed with the SEC is 1 Marina Park Drive, Boston, MA 02210, USA.

Insiders trading at Intercept Pharmaceuticals Inc

Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over 1,530,243,701$ worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth 77,118,364$ . The most active insiders traders include Srinivas Akkaraju、Jonathan Silverstein、Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of 1,114,673$. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth 5,017,290$.

What does Intercept Pharmaceuticals Inc do?

we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.

Complete history of Daniel Regan stock trades at Intercept Pharmaceuticals Inc

Intercept Pharmaceuticals Inc executives and stock owners

Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Mark Pruzanski,
  President, Chief Executive Officer, Director
• Jerome Durso,
  Chief Operating Officer
• Ryan Sullivan,
  General Counsel, Secretary
• Richard Kim,
  President, U.S. Commercial & Strategic Marketing
• Sandip Kapadia,
  Chief Financial Officer, Treasurer
• Gail Cawkwell,
  Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
• Lisa Bright,
  President, International
• David Ford,
  Chief Human Resource Officer
• Dr. Mark Pruzanski M.D.,
  Founder, Advisor & Director
• Jerome B. Durso,
  Pres, CEO & Director
• Paolo Fundaro,
  Independent Chairman of the Board
• Gino Santini,
  Lead Independent Director
• Glenn Sblendorio,
  Independent Director
• Daniel Welch,
  Independent Director
• Daniel Bradbury,
  Independent Director
• Luca Benatti,
  Independent Director
• Nancy Miller-Rich,
  Independent Director
• Keith Gottesdiener,
  Independent Director
• Srinivas Akkaraju,
  Independent Director
• Jason Campagna,
  Chief Medical Officer
• Christian Weyer,
  Executive Vice President - Research & Development
• Linda M. Richardson,
  Exec. VP & Chief Commercial Officer
• Jared M. Freedberg J.D.,
  Gen. Counsel
• Lisa M. DeFrancesco,
  Sr. VP of Corp. Affairs & Investor Relations
• Rocco Venezia,
  Chief Accounting Officer & Treasurer
• Bryan Ball,
  Chief Quality Officer & Sr. VP of Operations
• Andrew Saik,
  Chief Financial Officer
• Barbara Gayle Duncan,
  Chief Financial Officer
• Rachel Mc Minn,
  Chief Strategy Officer
• David Shapiro,
  Chief Medical Officer
• Linda M Richardson,
  EVP & Chief Commercial Officer
• S.P.A. Genextra,
  
• M Michelle Berrey,
  President, R&D and CMO
• Daniel Paul Regan,
  Chief Commerical Officer
• Jonathan Silverstein,
  Director
• Advisors Llc Orbi Med Capit...,
  
• Lorenzo Tallarigo,
  Director
• Klaus R Dr Veitinger,
  Director
• Sanj K Patel,
  Director
• Luciano Adorini,
  Chief Scientific Officer
• Nicole Williams,
  Director
• Francesco Micheli,
  
• Bryan Ball,
  Chief Qual. Officer & SVP Ops.
• Rocco Venezia,
  Chief Accounting Officer
• Dagmar Rosa Bjorkeson,
  Director
• Lisa De Francesco,
  SVP, IR & Corp. Affairs
• Jared Freedberg,
  General Counsel